Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
J Electrocardiol ; 79: 61-65, 2023.
Article in English | MEDLINE | ID: mdl-36963283

ABSTRACT

SARS-CoV-2 infection is associated with an increased risk of late cardiovascular (CV) outcomes. However, more data is needed to describe the electrophysiologic (EP) manifestation of post-acute CV sequelae of COVID-19. We compared two cohorts of adult patients with SARS-CoV-2 polymerase chain reaction (PCR) test and an electrocardiogram (ECG) performed between March 1, 2020, and September 13, 2020, in a retrospective double-cohort study, "Cardiovascular Risk Stratification in Covid-19" (CaVaR-Co19; NCT04555187). Patients with positive PCR comprised a COVID-19(+) cohort (n = 41; 61% women; 80% symptomatic), whereas patients with negative tests formed the COVID-19(-) cohort (n = 155; 56% women). In longitudinal analysis, comparing 3 ECGs recorded before, during, and on average 40 days after index COVID-19 episode, after adjustment for demographic and socioeconomic characteristics, baseline CV risk factors and comorbidities, use of prescription medications (including QT-prolonging drugs) before and during index COVID-19 episode, and the longitudinal changes in RR' intervals, heart rhythm, and ventricular conduction type, only in the COVID-19(+) cohort QTc increased by +30.2(95% confidence interval [CI] 0.1-60.3) ms and the spatial ventricular gradient (SVG) elevation increased by +13.5(95%CI 1.2-25.9)°. In contrast, much smaller, statistically nonsignificant changes were observed in the COVID-19(-) cohort. In conclusion, post-acute CV sequelae of SARS-CoV-2 infection manifested on ECG by QTc prolongation and rotation of the SVG vector upward.


Subject(s)
COVID-19 , Long QT Syndrome , Adult , Female , Humans , Male , Cohort Studies , Disease Progression , Electrocardiography , Hydroxychloroquine/therapeutic use , Long QT Syndrome/chemically induced , Retrospective Studies , SARS-CoV-2
2.
Am J Hypertens ; 32(10): 960-967, 2019 09 24.
Article in English | MEDLINE | ID: mdl-31070706

ABSTRACT

BACKGROUND: Hypertension is a significant risk factor for cardiovascular disease, a leading cause of death among people living with HIV (PLWH). Studies suggest that hypertension prevalence among PLWH is high, yet none assess how the 2017 redefinition of hypertension as ≥130/80 rather than the previous standard of ≥140/90 mm Hg will affect prevalence among PLWH. This study addresses this gap. METHODS: We examined medical record abstractions of 957 PLWH in Texas from the 2013-2014 Medical Monitoring Project survey. Participants with hypertension were identified by charted diagnosis, antihypertensive medication use, or blood pressure readings ≥140/90 and ≥130/80 mm Hg. Associations with sociodemographic and clinical variables were assessed using Rao-Scott chi-square tests, and odds of having hypertension were calculated using multivariable logistic regression models while adjusting for several demographic and HIV-related variables. RESULTS: The 2017 redefinition of hypertension increased prevalence in the sample by 44.3%, from 47.6% to 68.7%. Age group, body mass index, sex, and race remained significantly associated with hypertension (all P < 0.01). Although prevalence was near equal between males and females at ≥140/90 mm Hg (47.4% and 48.5%, respectively), males were 2.36 times more likely to have hypertension than females (95% confidence interval [CI]: 1.55-3.60) at ≥130/80 mm Hg. Prevalence remained comparable between white (73.3%) and black participants (72.9%). CONCLUSIONS: This study shows that hypertension prevalence is remarkably high among PLWH and is further increased by updated guidelines. Barriers to hypertension control in the HIV care setting should be identified and addressed to facilitate continued improvement in the quality and length of life for PLWH.


Subject(s)
Blood Pressure Determination/standards , Blood Pressure , HIV Infections/epidemiology , HIV Long-Term Survivors , Hypertension/diagnosis , Hypertension/epidemiology , Practice Guidelines as Topic , Adolescent , Adult , Age Distribution , Anti-HIV Agents/therapeutic use , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Comorbidity , Cross-Sectional Studies , Databases, Factual , Female , HIV Infections/diagnosis , HIV Infections/drug therapy , Humans , Hypertension/drug therapy , Hypertension/physiopathology , Male , Middle Aged , Predictive Value of Tests , Prevalence , Race Factors , Risk Assessment , Risk Factors , Sex Distribution , Texas/epidemiology , Young Adult
3.
Wounds ; 28(10): 347-353, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27768572

ABSTRACT

BACKGROUND: In recent years, a new technology for autologous epidermal harvesting has been developed to produce epidermal skin grafts (ESGs) for use over wounds. This technology employs negative pressure and heat to raise the epidermal skin layer, allowing for consistent and reproducible epidermal harvesting. The aim of this case series is to present the authors' experience using an automated, epidermal harvesting system to produce ESGs to treat wounds of patients with multiple comorbidities. MATERIALS AND METHODS: This case series was conducted between January 1, 2013 and December 31, 2014. Patients with wounds (≤ 25 cm2) that failed to heal were treated with ESGs by a group of 3 wound care physicians in 2 outpatient wound care centers in a community health center setting. RESULTS: A total of 94 patients with 102 wounds were identified. Of the 94 patients, 3 were noncompliant and 9 were lost to follow-up. Therefore, 82 patients with 90 wounds were included in the analysis. The majority of wounds demonstrated epithelialization (83/90, 92.2%). Of the 90 wounds, 75 (83.3%) healed following epidermal grafting, 4 (4.4%) wounds displayed improvement, and 11 (12.2%) did not heal. Minimal or no pain at the donor site was reported by the patients, and all donor sites healed without complications. CONCLUSION: This case series provides additional evidence for the use of ESGs for the treatment of wounds that fail to heal.


Subject(s)
Debridement/methods , Skin Transplantation , Trauma Centers , Wounds and Injuries/therapy , Adult , Aged , Epidermis/transplantation , Female , Graft Survival , Humans , Lost to Follow-Up , Male , Middle Aged , Practice Guidelines as Topic , Tissue and Organ Harvesting , Treatment Outcome , Wound Healing , Wounds and Injuries/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...